News | Radiopharmaceuticals and Tracers | August 31, 2015

NorthStar Medical Radioisotopes to Begin Production of Molybdenum-99

Company will regularly operate aliquoting line at University of Missouri Research Reactor

NorthStar Medical Radioisotopes, approval, routine production, Molybdenum-99, Mo-99, University of Missouri Research Reactor, MURR

August 31, 2015 — NorthStar Medical Radioisotopes LLC has received approval to begin routine production of molybdenum-99 (Mo-99) at the University of Missouri Research Reactor (MURR) facility in Columbia, Missouri. The company will now be able to regularly operate its proprietary aliquoting system at the MURR site to fill source vessels with Mo-99, enabling the company to establish a weekly production schedule and increase its output of the vital medical radioisotope.

This transitioning of NorthStar’s Mo-99 line at MURR from a development process to a routine production process is another significant step toward establishment of a domestic source of Mo-99. The company can immediately boost its output at MURR to as much as 200 six-day curies per process; a curie (Ci) is a unit of radioactivity and six-day Ci is the number of curies present in a shipment of Mo-99 six days after it leaves the producer’s facility. NorthStar also will be able to further increase its Mo-99 output at MURR after the production process receives final approval from the U.S. Food and Drug Administration (FDA).

Mo-99 is the parent isotope of technetium-99m (Tc-99m), the most widely used radioisotope in medical diagnostic imaging. Currently, nearly all Mo-99 is generated using weapons-useable highly enriched uranium (HEU) at aging facilities located outside of the United States, leading to chronic product shortages and creating safety and national security concerns. NorthStar utilizes two technologies for producing Mo-99 from stable isotopes of molybdenum without the use of HEU – a neutron capture process wherein MURR supplies Mo-99 under its Drug Master File, and an accelerator process using Mo-100.

The next significant step in the regulatory approval process will be submission of a final amendment to NorthStar’s New Drug Application (NDA) with the FDA. This is expected to occur late this year, according to James Harvey, Ph.D., NorthStar senior vice president and chief science officer. The company anticipates ultimately producing up to 3,000 six-day Ci at MURR.

For more information: www.northstarnm.com

Related Content

News | Nuclear Imaging

April 13, 2022 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the American Society of Nuclear ...

Home April 13, 2022
Home
Videos | Nuclear Imaging

American Society of Nuclear Cardiology (ASNC) President Dennis Calnon, M.D., MASNC, FASE, FSCCT, director of cardiac ...

Home February 01, 2022
Home
Feature | Nuclear Imaging | By Staff of the American Society of Nuclear Cardiology (ASNC)

A year after COVID-19 turned the world upside down, the American Society of Nuclear Cardiology (ASNC) asked members how ...

Home June 02, 2021
Home
News | Nuclear Imaging

April 1, 2021 – The ability to measure myocardial blood flow (MBF) as part of myocardial perfusion imaging (MPI) is one ...

Home April 01, 2021
Home
News | Nuclear Imaging

December 4, 2020 — Spectrum Dynamics Medical, Inc., has received Canadian Medical Device License from Health Canada for ...

Home December 04, 2020
Home
News | Nuclear Imaging

September 30, 2020 — Siemens Healthineers has introduced a new version of its c.cam dedicated cardiac nuclear medicine ...

Home October 07, 2020
Home
Feature | Nuclear Imaging | Dave Fornell, Editor

There were a few key takeaways from the American Society of Nuclear Cardiology (ASNC) 2019 annual meeting in September ...

Home November 22, 2019
Home
Videos | Nuclear Imaging

Rob Beanlands, M.D., FASNC, 2019 American Society of Nuclear Cardiology (ASNC) president, shares a couple trends he sees ...

Home November 07, 2019
Home
Videos | Nuclear Imaging

Robert C. Hendel, M.D., explains some of the new cardiac radiotracers in the pipeline that were discussed in sessions at ...

Home November 06, 2019
Home
Feature | Nuclear Imaging | Christopher A. Hanson M.D., and Jamieson M. Bourque M.D., MHS

Cardiac amyloidosis is a highly morbid and underdiagnosed infiltrative cardiomyopathy that is characterized by the ...

Home July 22, 2019
Home
Subscribe Now